Across TCGA pan-cancer cohorts, LHFPL6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LHFPL6 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LHFPL6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LHFPL6 expression acts as an unfavorable survival marker.

LUAD, PDAC, and LSCC are the cancer types where LHFPL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.193	1.000	.002	34	view →
PDAC	OS	Median	All	0.192	0.572	.021	5	view →
LSCC	DFS	Quartile	II,III,IV	0.868	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LHFPL6 tumor-vs-normal RNA expression · all LHFPL6 data types